Nefopam enantiomers: Preclinical pharmacology/toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration

化学 药代动力学 药理学 对映体 临床药理学 立体化学 医学
作者
Gary Mather,Rita Labroo,Marie–Emmanuelle Le Guern,F. Lepage,J. M. Gillardin,Ren� H. Levy
出处
期刊:Chirality [Wiley]
卷期号:12 (3): 153-159 被引量:32
标识
DOI:10.1002/(sici)1520-636x(2000)12:3<153::aid-chir9>3.0.co;2-v
摘要

Nefopam (NEF) is a potent analgesic compound administered as a racemic mixture. Previous in vitro and in vivo studies with nefopam enantiomers have shown that (+)nefopam [(+)NEF] is substantially more potent than (-)nefopam [(-)NEF]. Differences between enantiomers have also been suggested in metabolic studies in vitro. The impact of these differences in vivo is not known because there is little or no information on the relative plasma concentrations of the enantiomers or on their kinetics. In this study, individual enantiomers of nefopam were synthesized and examined for acute toxicity in male and female rats and mice. Pharmacologic properties of enantiomers were examined using in vitro binding assays and antinociceptive tests in rats and mice. Additionally, a pharmacokinetic study was conducted in human volunteers. Subjects were administered 20 mg nefopam as Acupan(R) either as a 5- or 20-min intravenous infusion. In a control phase, subjects were administered only vehicle. Blood samples were collected through the following 24 h. Plasma samples were analyzed for individual enantiomers using a chiral assay developed for this purpose. The pharmacologic differences of previous studies were confirmed in receptor binding assays and in the hot plate and the formalin tests in mice. Neither enantiomer demonstrated substantial activity in the tail flick test in rats. No significant differences were revealed between LD(50) values of nefopam enantiomers after oral or intravenous administration in male and female rats or mice. There were no significant differences in AUC(0-infinity), C(max), or half-life between enantiomers following intravenous administration. Based on these findings, there is currently no compelling rationale to justify administering or monitoring individual enantiomers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
在水一方的应助被111采纳,获得10
1秒前
华仔的应助被DW采纳,获得10
3秒前
3秒前
充电宝的应助被史萌采纳,获得10
3秒前
SciGPT的应助被星辰采纳,获得10
4秒前
5007完成签到,获得积分10
4秒前
4秒前
5秒前
西麓麓发布了新的文献求助10
6秒前
所所的应助被白华苍松采纳,获得10
6秒前
6秒前
syvshc的应助被科研通管家采纳,获得10
7秒前
momo完成签到,获得积分10
7秒前
Hello的应助被科研通管家采纳,获得10
7秒前
科研大人完成签到,获得积分10
7秒前
羊羊羊完成签到,获得积分10
7秒前
无花果的应助被科研通管家采纳,获得10
7秒前
丘比特的应助被科研通管家采纳,获得10
7秒前
思源的应助被科研通管家采纳,获得10
7秒前
星辰大海的应助被科研通管家采纳,获得10
7秒前
7秒前
7秒前
8秒前
8秒前
大模型的应助被科研通管家采纳,获得10
8秒前
情怀的应助被科研通管家采纳,获得10
8秒前
8秒前
852的应助被科研通管家采纳,获得10
8秒前
秋风的应助被科研通管家采纳,获得10
8秒前
wanci的应助被科研通管家采纳,获得10
8秒前
Scarlett的应助被科研通管家采纳,获得10
8秒前
赘婿的应助被科研通管家采纳,获得10
9秒前
Eau驳回了fantasy的应助
10秒前
某某完成签到,获得积分10
12秒前
Nole的应助被淡淡的小蜜蜂采纳,获得10
12秒前
月亮打烊完成签到 ,获得积分10
12秒前
13秒前
ShiqingZhao发布了新的文献求助10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188339
求助须知:如何正确求助?哪些是违规求助? 9576127
关于积分的说明 21845709
捐赠科研通 7786389
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482196